Literature DB >> 16302038

WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).

Shanthi Mendis1, Dele Abegunde, Salim Yusuf, Shah Ebrahim, Gerry Shaper, Hassen Ghannem, Bakuti Shengelia.   

Abstract

OBJECTIVE: To determine the extent of secondary prevention of coronary heart disease (CHD) and cerebrovascular disease (CVD) in low- and middle-income countries.
METHODS: A descriptive cross-sectional survey of a sample of 10 000 CHD (85.2%) and CVD (14.8%) patients (6252 men; 3748 women) was conducted over 6 months in geographically defined areas. The mean age was 59.2 years (standard deviation (SD), 10.8). Consecutive patients were recruited from a stratified random sample of primary, secondary and tertiary care facilities in defined areas in 10 countries (Brazil, Egypt, India, Indonesia, Islamic Republic of Iran, Pakistan, Russian Federation, Sri Lanka, Tunisia and Turkey). The main outcome measures were levels of lifestyle and physiological risk factors, and the use of drugs for secondary prevention of CHD and CVD.
FINDINGS: Approximately 82%, 89% and 77% of patients were aware of the cardiovascular benefits of quitting smoking, a heart-healthy diet and regular physical activity, respectively. About half (52.5%) engaged in less than 30 minutes of physical activity per day, 35% did not follow a heart-healthy diet and 12.5 % were current tobacco users. Blood pressure had been measured in 93.8% (range 71-100%), blood cholesterol in 85.5% (range 29-97%) and blood sugar in 75.5% (range 65-99%) in the preceding 12 months. The proportions who had received medications among CHD and CVD patients were: aspirin, 81.2%, 70.6%; beta-blockers, 48.1%, 22.8%; angiotensin-converting enzyme inhibitor, 39.8%, 37.8%; statins, 29.8%, 14.1%, respectively. About one-fifth of patients with CHD had undergone revascularization.
CONCLUSION: A significant proportion of patients did not receive appropriate medications. About 47% of patients had at least two or more modifiable risk factors (smoking, physical inactivity, hypertension, diabetes or hypercholesterolaemia). There are considerable missed opportunities for prevention of recurrences in those with established CVD in low- and middle-income countries.

Entities:  

Mesh:

Year:  2005        PMID: 16302038      PMCID: PMC2626468          DOI: /S0042-96862005001100011

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  79 in total

Review 1.  Polypill: lights and shadows.

Authors:  Koon K Teo; Yan Liang
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

3.  The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.

Authors:  Shanti Mendis; Keiko Fukino; Alexandra Cameron; Richard Laing; Anthonio Filipe; Oussama Khatib; Jerzy Leowski; Margaret Ewen
Journal:  Bull World Health Organ       Date:  2007-04       Impact factor: 9.408

Review 4.  Perspectives on the management of coronary artery disease in India.

Authors:  Ganesan Karthikeyan; Denis Xavier; Doriaraj Prabhakaran; Prem Pais
Journal:  Heart       Date:  2007-11       Impact factor: 5.994

Review 5.  Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.

Authors:  Ginés Sanz; Valentin Fuster
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

6.  Prevention: coronary artery calcium and polypill therapy.

Authors:  Ruth Webster; Anthony Rodgers
Journal:  Nat Rev Cardiol       Date:  2013-11-26       Impact factor: 32.419

7.  Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease.

Authors:  Krishna Kumar Sharma; Mukul Mathur; Rakesh Gupta; Soneil Guptha; Sanjeeb Roy; R S Khedar; Nishant Gupta; Rajeev Gupta
Journal:  Indian Heart J       Date:  2013-04-09

Review 8.  Treating to protect: current cardiovascular treatment approaches and remaining needs.

Authors:  Michael Böhm; Christian Werner; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Journal:  Medscape J Med       Date:  2008-03-26

Review 9.  Resource Effective Strategies to Prevent and Treat Cardiovascular Disease.

Authors:  J D Schwalm; Martin McKee; Mark D Huffman; Salim Yusuf
Journal:  Circulation       Date:  2016-02-23       Impact factor: 29.690

Review 10.  Hepatitis B virus infection and risk of coronary artery disease: a meta-analysis.

Authors:  Karn Wijarnpreecha; Charat Thongprayoon; Panadeekarn Panjawatanan; Patompong Ungprasert
Journal:  Ann Transl Med       Date:  2016-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.